Risperidone 3 mg
DrugParticipants will receive 3 mg oral risperidone tablet once daily for 3 days.
NCT Number: NCT04940039
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month [PP1M] and 3-month [PP3M] formulations).
Looking for future studies?
Notify Me19 year–34 year
All sexes
Interventional
Phase 4
University Teaching Hospital of Butare(CHUB), Butare, Rwanda
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
Other names: R092670
Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
Other names: R092670
Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
Other names: R092670
Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
Other names: R092670
Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
Other names: R092670
Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
Other names: R092670
Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
Other names: R092670
Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
Other names: R092670
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Up to Week 66
An adverse event is any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events are adverse events with onset after the initiation of treatment in observation phase and separately for initiation of paliperidone palmitate (PP) in Lead-in phase or that are a consequence of a pre-existing condition that has worsened after each treatment phase starts.
Time frame: Up to Week 66
Number of participants with abnormalities in clinical laboratory measures (including serum chemistry, hematology and urinalysis) will be reported.
Time frame: Up to Week 66
Number of participants with abnormalities in vital signs (temperature [oral], pulse/heart rate, and blood pressure) will be reported.
Time frame: Up to Week 66
Number of participants with abnormalities in ECG will be reported.
Time frame: Up to Week 66
Number of participants with abnormalities in physical examination (including body weight, waist circumference, and height) will be reported.
Time frame: Up to Week 66
Number of participants with pregnancy outcome will be reported.
Time frame: Visit 12 (Week 46) to Visit 14 (Week 66 [EOS])
C-SSRS is an approved and standardized scale for the assessment of the severity of suicidality, through clinical interview. The maximum score assigned for each participant will be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity. Number of participants with suicidal ideation and behavior will be reported.
Janssen-Cilag International NV
Industry
Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Acronym: CASPAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05838573
Cognition Disorders, Cognitive Dysfunction
Changsha, Hunan, China
View Trial DetailsNCT05304767
Mental Disorders, Schizophrenia
Phoenix, Arizona, United States
View Trial DetailsNCT00004571
Mental Disorders, Normal Physiology
Bethesda, Maryland, United States
View Trial DetailsNCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial Details